Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 112Breast Neoplasms 17Neoplasms 7Leiomyoma 6Prostate Adenocarcinoma 3Polycystic Ovary Syndrome 3Salivary Gland Neoplasms 2Neoplasm Metastasis 2Multiple Myeloma 2Lymphoma, Non-Hodgkin 2Uveal Melanoma 1Stage I Prostate Adenocarcinoma AJCC v7 1Sleep Apnea, Obstructive 1Skin Neoplasms 1Sexual Dysfunctions, Psychological 1Sexual Dysfunction, Physiological 1Salivary Gland Neoplasm Duct 1Recurrence 1Puberty, Precocious 1Primary Dysautonomias 1Premenopausal Breast Cancer 1Patient Compliance 1PSA Level Greater Than Two 1Obesity, Morbid 1Obesity 1Myofibroma 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Metabolic Syndrome 1Melanoma 1

Interventions

luprolide acetate gel depot 1enzalutamide 1Triptorelin Pamoate 1Radiosurgery 1Leuprolide 1Goserelin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Castration-resistant Prostate Cancer Patients with Oligometastases × Leuprolide × Clear all
NCT02685397 2024-12-04

PCS IX

Sir Mortimer B. Davis - Jewish General Hospital

Phase 2/3 Active not recruiting
102 enrolled
Genitourinary

Castration-resistant Prostate Cancer Patients with Oligometastases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡